Clinical trial · Interventional
Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer
Pharmacokinetics Study of Combined Treatment Lapatinib and Tamoxifen in Advanced/Metastatic Breast Cancer
NCT00424164CI-TRIAL-00074834LAPATAMcompletedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells. Giving lapatinib together with tamoxifen may be an effective treatment for breast cancer. PURPOSE: This randomized phase I trial is studying the side effects of lapatinib and tamoxifen in treating patients with advanced or metastatic breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Tamoxifen-lapatinib
- description
- Tamoxifen alone at cycle 1 and as of cycle 2 in combination with Lapatinib.
- interventionNames
- Drug: lapatinib ditosylate
- Drug: tamoxifen citrate
- Other: pharmacological study
- type
- EXPERIMENTAL
- label
- Lapatinib-tamoxifen
- description
- Lapatinib will be given alone for 2 weeks during cycle 1. As of cycle 2, you will receive the combined treatment Lapatinib and Tamoxifen
- interventionNames
- Drug: lapatinib ditosylate
- Drug: tamoxifen citrate
- Other: pharmacological study
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed advanced or metastatic breast cancer * Progressive disease after aromatase inhibitor therapy * Hormone receptor status: * Estrogen receptor- and/or progesterone receptor-positive tumor * Patients with stable brain metastases (i.e., no neurological symptoms and no corticosteroid treatment) are eligible PATIENT CHARACTERISTICS: * Male or female * Menopausal status not specified * ECOG performance status 0-2 * Life expectancy ≥ 12 weeks * Neutrophil count \> 1,500/mm³ * Platelet count \> 100,000/mm³ * AST and/or ALT \< 3 times upper limit of normal (ULN) * Creatinine \< 1.5 times ULN * Bilirubin \< 1.5 times ULN * Clinically normal cardiac function (i.e., LVEF normal by MUGA or ECHO) * No current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases, or stable chronic live disease) * No ischemic heart disease within the past 6 months * Normal 12-lead ECG * No active or uncontrolled infections * No serious illnesses or medical conditions, including any of the following: * Hypercalcemia * Malabsorption syndrome * Chronic alcohol abuse * Hepatitis * HIV * Cirrhosis * Able to swallow and retain oral medication * No psychological, familial, sociological, or geographical condition potentially hampering study compliance * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after completion of study treatment PRIOR CONCURRENT THERAPY: * See Disease Characteristics * At least 2 days since prior and no concurrent inducers or inhibitors of CYP3A4, including any of the following: * Rifabutin * Clarithromycin * Cyclosporine * Voriconazole * Fluoxetine * Paroxetine * Midazolam * Isoniazid * Dihydralazine * Digitoxin * Coumadin * Phenytoin * Verapamil * Diltiazem * Herbal constituents (e.g., bergamottin and glabridin) * At least 2 weeks since prior aromatase inhibitor * Aromatase inhibitors in the adjuvant and/or metastatic setting allowed * At least 1 year since prior tamoxifen citrate * No other concurrent anticancer therapy or investigational agents
References
Publications (1)
- DERIVEDFumoleau P, Koch KM, Brain E, Lokiec F, Rezai K, Awada A, Hayward L, Werutsky G, Bogaerts J, Marreaud S, Cardoso F. A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study). Breast. 2014 Oct;23(5):663-9. doi: 10.1016/j.breast.2014.07.003. Epub 2014 Jul 24. PMID 25065668